180 related articles for article (PubMed ID: 16980988)
21. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
22. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
23. Donor CD31 genotype and its association with acute graft-versus-host disease in HLA identical sibling stem cell transplantation.
Goodman RS; Ewing J; Evans PC; Craig J; Poulton K; Dyer PA; Marcus RE; Taylor CJ
Bone Marrow Transplant; 2005 Jul; 36(2):151-6. PubMed ID: 15908974
[TBL] [Abstract][Full Text] [Related]
24. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
26. Immunogenic disparities of 11 minor histocompatibility antigens (mHAs) in HLA-matched unrelated allogeneic hematopoietic SCT.
Markiewicz M; Siekiera U; Karolczyk A; Szymszal J; Helbig G; Wojnar J; Dzierzak-Mietla M; Kyrcz-Krzemien S
Bone Marrow Transplant; 2009 Feb; 43(4):293-300. PubMed ID: 18850018
[TBL] [Abstract][Full Text] [Related]
27. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
29. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
30. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect.
Huang XJ; Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX
Bone Marrow Transplant; 2009 Sep; 44(5):309-16. PubMed ID: 19234512
[TBL] [Abstract][Full Text] [Related]
31. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
32. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival.
Loiseau P; Busson M; Balere ML; Dormoy A; Bignon JD; Gagne K; Gebuhrer L; Dubois V; Jollet I; Bois M; Perrier P; Masson D; Moine A; Absi L; Reviron D; Lepage V; Tamouza R; Toubert A; Marry E; Chir Z; Jouet JP; Blaise D; Charron D; Raffoux C
Biol Blood Marrow Transplant; 2007 Aug; 13(8):965-74. PubMed ID: 17640601
[TBL] [Abstract][Full Text] [Related]
33. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
34. Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation.
Stern M; Passweg J; Tiercy JM; Genitsch A; Meyer-Monard S; Heim D; Tichelli A; Gratwohl A; Nissen-Druey C
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1169-75. PubMed ID: 17085310
[TBL] [Abstract][Full Text] [Related]
35. Risk factors in pediatric stem cell transplantation for leukemia.
Gustafsson Jernberg A; Remberger M; Ringdén O; Winiarski J
Pediatr Transplant; 2004 Oct; 8(5):464-74. PubMed ID: 15367282
[TBL] [Abstract][Full Text] [Related]
36. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
37. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
[TBL] [Abstract][Full Text] [Related]
38. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
39. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
40. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation.
Gallardo D; Aróstegui JI; Balas A; Torres A; Caballero D; Carreras E; Brunet S; Jiménez A; Mataix R; Serrano D; Vallejo C; Sanz G; Solano C; Rodríguez-Luaces M; Marín J; Baro J; Sanz C; Román J; González M; Martorell J; Sierra J; Martín C; de la Cámara R; Grañena A;
Br J Haematol; 2001 Sep; 114(4):931-6. PubMed ID: 11564088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
